Skip to content
Tablet Allopathic

Renocal Plus 435 mg+ 235 mg tablet

Generic: Calcium acetate + Magnesium carbonate

Company: Everest Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength435 mg+ 235 mg
PackStrip: 100.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated April 23, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Calcium acetate + Magnesium carbonate 435 mg+ 235 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Renocal Plus (this medicine)10.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Calcium acetate + Magnesium carbonate guide

Indications

This is indicated in the treatment of hyperphosphatemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis). This is indicated in adults.

Dosage and administration

Adults: 3 to 10 film-coated tablets per day, depending on the serum phosphate level. The daily dose should be subdivided according to the number of meals per the day (usually 3 a day). The recommended starting dose is 3 tablets daily. If necessary, the dosage may be raised to maximally 12 film-coated tablets per day. Pediatric population: The safety and efficacy of this tablet in children and adolescence have not been established. Therefore, the administration of this tablet is not recommended in children and adolescents below 18 years of age. Method of administration:To achieve the maximum phosphate binding effect, this tablet must be taken together with the meal and should not be crushed or chewed. For easy swallowing, the tablets should be taken together with some liquid. In case the tablets are too large to be swallowed by the patient, the tablets should be broken along the score line immediately before swallowing in order to avoid the development of taste of acetic acid. Because the rate and/or extent of absorption of other defined medicinal products may vary when used concomitantly with this tablet, none of the oral medicinal products should be taken within the period 2 hours before and 3 hours after administration of this tablet. This can be applied long-term.

Side effects

Gastrointestinal disorders: Soft stools, gastrointestinal irritation like nausea, anorexia, sensation of fullness, belching and constipation, diarrhoea. Metabolism and nutrition disorders: Hypercalcaemia either asymptomatic or symptomatic, asymptomatic hypermagnesaemia.

Precautions and warnings

The use of phosphate binders should be preceded by a dietary consultation with the patient concerning phosphate uptake, and may depend on the kind of dialysis treatment the patient is receiving. This tablet should only be administered with caution (only with continuous monitoring of serum calcium, magnesium and phosphate) in case of severe hyperphosphataemia with a calcium-phosphate-product of more than 5.3 mmol 2/l2 if refractory to therapy, refractory hyperkalaemia, clinical relevant bradycardia or AV-block II° with bradycardia. Continuous monitoring of serum phosphate, serum magnesium, serum calcium and the calcium-phosphate-product should be performed, especially in case of simultaneous intake of vitamin D preparations and thiazide diuretics. High doses and long-term administration of this tablet may result in hypermagnesaemia. Hypermagnesaemia is mostly asymptomatic, but in some cases systemic effects may be seen. For symptoms and management of hypermagnesaemia and hypercalcaemia please see section 4.9. Patients should be advised to seek medical advice before taking antacids containing calcium or magnesium salts to avoid adding to the calcium or magnesium load. If patients with a chronic renal insufficiency receive this tablet they may develop hypercalcaemic episodes, especially in combination with the administration of metabolites of vitamin D. Patients should be warned of the possible symptoms of hypercalcaemia. During a long-term therapy with this tablet attention must be paid to the progression or the appearance of vascular and soft tissue calcifications. The risk decreases by lowering the calcium-phosphate-product to < 4.5 mmol2/l2. In patients receiving digitalis glycosides, this tablet should only be administered under ECG control and monitoring of the serum calcium level. Increased intake of calcium salts may result in the precipitation of fatty acids and bile acid as calcium soap. This may lead to constipation. In case of diarrhoea the dosage of this tablet should be reduced. this tablet contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. This tablet contains sodium. This has to be taken in consideration by patients on a controlled sodium diet. Paediatric population The safety and efficacy of this tablet in children and adolescence have not been established. Therefore, the administration of this tablet is not recommended in children and adolescents below 18 years of age.

Pregnancy and lactation

There are no or limited amount of data from the use of this tablet in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. This tablet should not be used during pregnancy unless the clinical condition of the woman requires treatment with calcium acetate and magnesium carbonate. Calcium acetate and magnesium carbonate are excreted in human milk to such an extent that effects on the breastfed newborns/infants are likely. Breast-feeding is not recommended during treatment with this tablet.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250